Cytokinetics Incorporated

Financials

Flusso di cassa derivante dalle attività operative -65.57 M-131.62 M-128.24 M-107.5 M-142.65 M -510.01 M Flussi di cassa derivanti dalle attività di investimento 110.86 M105.96 M52.88 M-70.98 M-71.19 M 16.67 M Liquidità derivante dalle attività di finanziamento 2.38 M4.75 M78.53 M330.47 M110.7 M 524.46 M Liquidità libera -66.86 M-137.28 M-132.38 M-116.86 M-148.29 M -534.82 M

Cytokinetics, Incorporated, is a biopharmaceutical company based in South San Francisco, California, that develops muscle activators and muscle inhibitors as potential treatments for people with diseases characterized by impaired or declining muscle function.

CYTK

Financials

Cytokinetics Incorporated

Notizie

EVP di Cytokinetics (CYTK) Malik vende azioni per 292.985 dollari

FOMC To Release Minutes Of March Meeting, Delta Air Lines Earnings In Focus

Evercore ISI conferma il rating su Cytokinetics in vista dei dati dello studio

Will Positive Camzyos Data Strengthen BMY's Cardiovascular Portfolio?

Why Is Cytokinetics (CYTK) Down 0.8% Since Last Earnings Report?

Mizuho alza il target su Cytokinetics a $100 per estensione IP

JPMorgan alza il target su Cytokinetics a 75 dollari

Cytokinetics stock price target raised to $75 by JPMorgan

Stifel conferma il rating su Cytokinetics prima dei dati dello studio

Stifel reiterates Cytokinetics stock rating ahead of trial data

Leerink conferma il rating su Cytokinetics per fiducia nel lancio

Leerink reiterates Cytokinetics stock rating on launch confidence